{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T05:57:06Z","timestamp":1763704626489},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"S1","license":[{"start":{"date-parts":[[2010,4,1]],"date-time":"2010-04-01T00:00:00Z","timestamp":1270080000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2010,4]]},"DOI":"10.1038\/sj.bjc.6605600","type":"journal-article","created":{"date-parts":[[2010,4,13]],"date-time":"2010-04-13T01:04:18Z","timestamp":1271120658000},"page":"S10-S16","source":"Crossref","is-referenced-by-count":21,"title":["Primary prevention of venous thromboembolism in medical and surgical oncology patients"],"prefix":"10.1038","volume":"102","author":[{"given":"A","family":"Stanley","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Young","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2010,4,13]]},"reference":[{"key":"BF6605600_CR1","doi-asserted-by":"crossref","unstructured":"Agnelli G, Bergqvist D, Cohen AT, Gallus AS, Gent M, on behalf of PEGASUS investigators. Randomized clinical trial of postoperative fondaparinux vs perioperative dalteparin for prevention of venous thromboembolism in high-risk abdominal surgery. Br J Surg 92: 1212\u20131220","DOI":"10.1002\/bjs.5154"},{"key":"BF6605600_CR2","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1200\/JCO.2005.04.2150","volume":"24","author":"A Alcalay","year":"2006","unstructured":"Alcalay A, Wun T, Khatri V, Chew HK, Harvey D, Zhou H, White RH (2006) Venous thromboembolism in patients with colorectal cancer: incidence and effect on survival. J Clin Oncol 24: 1112\u20131118","journal-title":"J Clin Oncol"},{"key":"BF6605600_CR3","first-page":"2558","volume":"296","author":"CL Bennett","year":"2006","unstructured":"Bennett CL, Angelotta C, Yarnold PR, Evens AM, Zonder JA, Raisch DW, Richardson P (2006) Thalidomide- and lenalidomide-associated thromboembolism among patients with cancer. JAMA 296: 2558\u20132560","journal-title":"JAMA"},{"key":"BF6605600_CR4","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1056\/NEJMoa012385","volume":"346","author":"D Bergqvist","year":"2002","unstructured":"Bergqvist D, Agnelli G, Cohen AT, Eldor A, Nilsson PE, Le Moigne-Amrani A, Dietrich-Neto F, for ENOXACAN II investigators (2002) Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer. N Engl J Med 346: 975\u2013980","journal-title":"N Engl J Med"},{"key":"BF6605600_CR5","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1001\/jama.293.6.715","volume":"293","author":"JW Blom","year":"2005","unstructured":"Blom JW, Doggen CJ, Osanto S, Rosendaal FR (2005) Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA 293: 715\u2013722","journal-title":"JAMA"},{"key":"BF6605600_CR6","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1055\/s-0038-1649881","volume":"74","author":"RD Bona","year":"1995","unstructured":"Bona RD, Sivjee KY, Hickey AD, Wallace DM, Wajcs SB (1995) The efficacy and safety of oral anticoagulation in patients with cancer. Thromb Haemost 74: 1055\u20131058","journal-title":"Thromb Haemost"},{"key":"BF6605600_CR7","doi-asserted-by":"publisher","first-page":"2272","DOI":"10.1182\/blood-2002-06-1674","volume":"100","author":"M Cavo","year":"2002","unstructured":"Cavo M, Zamagni E, Cellini C, Tosi P, Cangini D, Cini M, Valdr\u00e8 L, Palareti G, Masini L, Tura S, Baccarani M (2002) Deep vein thrombosis in patients with multiple myeloma receiving first-line thalidomide-dexamethasone therapy. Blood 100: 2272\u20132273","journal-title":"Blood"},{"key":"BF6605600_CR8","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1160\/TH07-07-0446","volume":"99","author":"P Chaukiyal","year":"2008","unstructured":"Chaukiyal P, Nautiyal A, Radhakrishnan S, Singh S, Navaneethan S (2008) Thromboprophylaxis in cancer patients with central venous catheters. A systematic review and meta-analysis. Thromb Haemost 99: 38\u201343","journal-title":"Thromb Haemost"},{"key":"BF6605600_CR9","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1001\/archinte.166.4.458","volume":"166","author":"HK Chew","year":"2006","unstructured":"Chew HK, Wun T, Harvey D, Zhou H, White RH (2006) Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch Intern Med 166: 458\u2013464","journal-title":"Arch Intern Med"},{"key":"BF6605600_CR10","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1097\/00000658-198808000-00016","volume":"208","author":"GP Clagett","year":"1998","unstructured":"Clagett GP, Reisch JS (1998) Prevention of venous thromboembolism in general surgical patients. Ann Surg 208: 227\u2013240","journal-title":"Ann Surg"},{"key":"BF6605600_CR11","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1136\/bmj.38733.466748.7C","volume":"332","author":"AT Cohen","year":"2006","unstructured":"Cohen AT, Davidson BL, Gallus AS, Lassen MR, Prins MH, Tomkowski W, Turpie AG, Egberts JF, Lensing AW, ARTEMIS Investigators (2006) Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial. BMJ 332: 325\u2013329","journal-title":"BMJ"},{"key":"BF6605600_CR12","doi-asserted-by":"publisher","first-page":"1958","DOI":"10.1016\/S0140-6736(09)60941-7","volume":"373","author":"M Dennis","year":"2009","unstructured":"Dennis M, Sandercock PA, Reid J, Graham C, Murray G, Venables G, Rudd A, Bowler G (2009) Effectiveness of thigh-length graduated compression stockings to reduce the risk of deep vein thrombosis after stroke (CLOTS trial 1): a multicentre, randomised controlled trial. CLOTS Trials Collaboration. Lancet 373: 1958\u20131965","journal-title":"Lancet"},{"key":"BF6605600_CR13","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1016\/S0140-6736(07)61445-7","volume":"370","author":"BI Eriksson","year":"2007","unstructured":"Eriksson BI, Dahl OE, Rosencher N, Kurth AA, van Dijk CN, Frostick SP, Prins MH, Hettiarachchi R, Hantel S, Schnee J, Buller HR, RE-NOVATE Study Group (2007a) Dabigatran etexilate vs enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet 370: 949\u2013956","journal-title":"Lancet"},{"key":"BF6605600_CR14","doi-asserted-by":"publisher","first-page":"2178","DOI":"10.1111\/j.1538-7836.2007.02748.x","volume":"5","author":"BI Eriksson","year":"2007","unstructured":"Eriksson BI, Dahl OE, Rosencher N, Kurth AA, van Dijk CN, Frostick SP, K\u00e4lebo P, Christiansen AV, Hantel S, Hettiarachchi R, Schnee J, B\u00fcller HR, RE-MODEL Study Group (2007b) Oral dabigatran etexilate vs subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J Thromb Haemost 5: 2178\u20132185","journal-title":"J Thromb Haemost"},{"key":"BF6605600_CR15","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1302\/0301-620X.91B5.21691","volume":"91","author":"BI Eriksson","year":"2009","unstructured":"Eriksson BI, Kakkar AK, Turpie AG, Gent M, Bandel TJ, Homering M, Misselwitz F, Lassen MR (2009) Oral rivaroxaban for the prevention of symptomatic venous thromboembolism after elective hip and knee replacement. J Bone Joint Surg Br 91: 636\u2013644","journal-title":"J Bone Joint Surg Br"},{"key":"BF6605600_CR16","doi-asserted-by":"publisher","first-page":"381S","DOI":"10.1378\/chest.08-0656","volume":"133","author":"WH Geerts","year":"2008","unstructured":"Geerts WH, Bergqvist D, Pineo GF, Heit JA, Samama CM, Lassen MR, Colwell CW (2008) Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133: 381S\u2013453S","journal-title":"Chest"},{"key":"BF6605600_CR17","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1001\/archinte.160.6.809","volume":"160","author":"JA Heit","year":"2000","unstructured":"Heit JA, Silverstein MD, Mohr DN, Petterson TM, O'Fallon WM, Melton III LJ (2000) Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern Med 160: 809\u2013815","journal-title":"Arch Intern Med"},{"key":"BF6605600_CR18","unstructured":"HES Online. Hospital Episodes Statistics 2007\u20132008. http:\/\/www.hesonline.org.uk\/Ease\/servlet\/ContentServer?siteID=1937&categoryID=193 . Accessed August 24, 2009"},{"key":"BF6605600_CR19","doi-asserted-by":"publisher","first-page":"141S","DOI":"10.1378\/chest.08-0689","volume":"133","author":"J Hirsh","year":"2008","unstructured":"Hirsh J, Bauer KA, Donati MB, Gould M, Samama MM, Weitz JI (2008) Parenteral anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133: 141S\u2013159S","journal-title":"Chest"},{"key":"BF6605600_CR20","doi-asserted-by":"publisher","first-page":"3078","DOI":"10.1200\/JCO.2000.18.17.3078","volume":"18","author":"BA Hutten","year":"2000","unstructured":"Hutten BA, Prins MH, Gent M, Ginsberg J, Tijssen JG, Buller HR (2000) Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: a retrospective analysis. J Clin Oncol 18: 3078\u20133083","journal-title":"J Clin Oncol"},{"key":"BF6605600_CR21","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1160\/TH08-07-0486","volume":"101","author":"X Jiang","year":"2009","unstructured":"Jiang X, Crain EJ, Luettgen JM, Schumacher WA, Wong PC (2009) Apixaban, an oral direct factor Xa inhibitor, inhibits human clot-bound factor Xa activity in vitro. Thromb Haemost 101: 780\u2013782","journal-title":"Thromb Haemost"},{"key":"BF6605600_CR22","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1634\/theoncologist.8-4-381","volume":"8","author":"AK Kakkar","year":"2003","unstructured":"Kakkar AK, Levine M, Pinedo HM, Wolff R, Wong J (2003) Venous thrombosis in cancer patients: insights from the FRONTLINE survey. Oncologist 8: 381\u2013388","journal-title":"Oncologist"},{"key":"BF6605600_CR23","doi-asserted-by":"publisher","first-page":"1944","DOI":"10.1200\/JCO.2004.10.002","volume":"22","author":"AK Kakkar","year":"2004","unstructured":"Kakkar AK, Levine MN, Kadziola Z, Lemoine NR, Low V, Patel HK, Rustin G, Thomas M, Quigley M, Williamson RC (2004) Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS). J Clin Oncol 22: 1944\u20131948","journal-title":"J Clin Oncol"},{"key":"BF6605600_CR24","doi-asserted-by":"publisher","first-page":"901.e1","DOI":"10.1016\/j.amjmed.2007.05.010","volume":"120","author":"A Kirkpatrick","year":"2007","unstructured":"Kirkpatrick A, Rathbun S, Whitsett T, Raskob G (2007) Prevention of central venous catheter-associated thrombosis: a meta-analysis. Am J Med 120: 901.e1\u2013901.e13","journal-title":"Am J Med"},{"key":"BF6605600_CR25","doi-asserted-by":"publisher","first-page":"2776","DOI":"10.1056\/NEJMoa076016","volume":"358","author":"MR Lassen","year":"2008","unstructured":"Lassen MR, Ageno W, Borris LC, Lieberman JR, Rosencher N, Bandel TJ, Misselwitz F, Turpie AG, RECORD3 Investigators (2008) Rivaroxaban vs enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med 358: 2776\u20132786","journal-title":"N Engl J Med"},{"key":"BF6605600_CR26","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1111\/j.1538-7836.2004.01094.x","volume":"3","author":"A Leizorovicz","year":"2005","unstructured":"Leizorovicz A, Turpie AG, Cohen AT, Wong L, Yoo MC, Dans A, for the SMART Study Group (2005) Epidemiology of venous thromboembolism in Asian patients undergoing major orthopedic surgery without thromboprophylaxis. The SMART Study. J Thromb Haemost 3: 28\u201334","journal-title":"J Thromb Haemost"},{"key":"BF6605600_CR27","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1245\/s10434-006-9183-9","volume":"14","author":"MJ Leonardi","year":"2006","unstructured":"Leonardi MJ, McGory ML, Ko CY (2006) A systematic review of deep venous thrombosis prophylaxis in cancer patients: implications for improving quality. Ann Surg Oncol 14: 929\u2013936","journal-title":"Ann Surg Oncol"},{"key":"BF6605600_CR28","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1016\/S0140-6736(94)90008-6","volume":"343","author":"M Levine","year":"1994","unstructured":"Levine M, Hirsh J, Gent M, Arnold A, Warr D, Falanga A, Samosh M, Bramwell V, Pritchard KI, Steward D, Warr D, Goodwin P, Samosh M, Falanga A (1994) Double-blind randomised trial of a very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancer. Lancet 343: 886\u2013889","journal-title":"Lancet"},{"key":"BF6605600_CR29","doi-asserted-by":"publisher","first-page":"5490","DOI":"10.1200\/JCO.2007.14.1283","volume":"25","author":"GH Lyman","year":"2007","unstructured":"Lyman GH, Khorana AA, Falanga A, Clarke-Pearson D, Flowers C, Jahanzeb M, Kakkar A, Kuderer NM, Levine MN, Liebman H, Mendelson D, Raskob G, Somerfield MR, Thodiyil P, Trent D, Francis CW (2007) American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol 25: 5490\u20135505","journal-title":"J Clin Oncol"},{"key":"BF6605600_CR30","doi-asserted-by":"crossref","unstructured":"Mandal\u00e1 M, Falanga A, Roila F, on behalf of ESMO Guidelines Working Group. Management of venous thromboembolism in cancer patients: ESMO clinical recommendations. Ann Oncol 19 (suppl 2): ii126\u2013ii127","DOI":"10.1093\/annonc\/mdn110"},{"key":"#cr-split#-BF6605600_CR31.1","unstructured":"4. National Institute for Health and Clinical Excellence (2009) Venous thromboembolism"},{"key":"#cr-split#-BF6605600_CR31.2","unstructured":"5. (VTE) risk assessment. http:\/\/www.dh.gov.uk\/en\/Publicationsandstatistics\/Publications\/PublicationsPolicyAndGuidance\/DH_088215 . Accessed August 24, 2009"},{"key":"BF6605600_CR32","unstructured":"National Institute for Health and Clinical Excellence (2010) Reducing the risk of venous thromboembolism (deep vein thrombosis and pulmonary embolism) in patients admitted to the hospital. http:\/\/www.nice.org.uk\/guidance\/index.jsp?action=byID&o=12695 . Accessed August 24, 2009."},{"key":"BF6605600_CR33","doi-asserted-by":"publisher","first-page":"3484","DOI":"10.1182\/blood-2002-01-0108","volume":"100","author":"P Prandoni","year":"2002","unstructured":"Prandoni P, Lensing AW, Piccioli A, Bernardi E, Simioni P, Girolami B, Marchiori A, Sabbion P, Prins MH, Noventa F, Girolami A (2002) Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood 100: 3484\u20133488","journal-title":"Blood"},{"key":"BF6605600_CR34","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1200\/JCO.2005.03.0221","volume":"24","author":"SV Rajkumar","year":"2006","unstructured":"Rajkumar SV, Blood E, Vesole D, Fonseca R, Greipp PR (2006) Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol 24: 431\u2013436","journal-title":"J Clin Oncol"},{"key":"BF6605600_CR35","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1056\/NEJM199909093411103","volume":"341","author":"MM Samama","year":"1999","unstructured":"Samama MM, Cohen AT, Darmon JY, Desjardins L, Eldor A, Janbon C, Leizorovicz A, Nguyen H, Olsson CG, Turpie AG, Weisslinger N, for the Prophylaxis in Medical Patients with Enoxaparin Study Group (1999) A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. N Engl J Med 341: 793\u2013800","journal-title":"N Engl J Med"},{"key":"BF6605600_CR36","first-page":"1020","volume":"9","author":"E Shantsila","year":"2008","unstructured":"Shantsila E, Lip GY (2008) Apixaban, an oral, direct inhibitor of activated factor Xa. Curr Opin Investig Drugs 9: 1020\u20131033","journal-title":"Curr Opin Investig Drugs"},{"key":"BF6605600_CR37","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1016\/S0140-6736(09)60734-0","volume":"373","author":"AG Turpie","year":"2009","unstructured":"Turpie AG, Lassen MR, Davidson BL, Bauer KA, Gent M, Kwong LM, Cushner FD, Lotke PA, Berkowitz SD, Bandel TJ, Benson A, Misselwitz F, Fisher WD, RECORD4 Investigators (2009) Rivaroxaban vs enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. Lancet 373: 1673\u20131680","journal-title":"Lancet"},{"key":"BF6605600_CR38","doi-asserted-by":"publisher","first-page":"311S","DOI":"10.1378\/chest.126.3_suppl.311S","volume":"126","author":"T Warkentin","year":"2004","unstructured":"Warkentin T, Greinacher A (2004) Heparin-induced thrombocytopenia: recognition, treatment, and prevention: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126: 311S\u2013337S","journal-title":"Chest"},{"key":"BF6605600_CR39","doi-asserted-by":"crossref","unstructured":"Young AM, Billingham LJ, Begum G, Kerr DJ, Hughes AI, Rea DW, Shepherd S, Stanley A, Sweeney A, Wilde J, Wheatley K, WARP Collaborative Group, UK. Warfarin thromboprophylaxis in cancer patients with central venous catheters (WARP): an open-label randomised trial. Lancet 373: 567\u2013574","DOI":"10.1016\/S0140-6736(09)60205-1"},{"key":"BF6605600_CR40","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1634\/theoncologist.10-1-72","volume":"10","author":"LR Zacharski","year":"2005","unstructured":"Zacharski LR, Prandoni P, Monreal M (2005) Warfarin vs low-molecular weight heparin therapy in cancer patients. Oncologist 10: 72\u201379","journal-title":"Oncologist"},{"key":"BF6605600_CR41","doi-asserted-by":"publisher","first-page":"1614","DOI":"10.1182\/blood.V98.5.1614","volume":"98","author":"M Zangari","year":"2001","unstructured":"Zangari M, Anaissie E, Barlogie B, Badros A, Desikan R, Gopal AV, Morris C, Toor A, Siegel E, Fink L, Tricot G (2001) Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy. Blood 98: 1614\u20131615","journal-title":"Blood"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/6605600.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/6605600","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/6605600.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T12:44:33Z","timestamp":1684413873000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/6605600"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,4]]},"references-count":42,"journal-issue":{"issue":"S1","published-print":{"date-parts":[[2010,4]]}},"alternative-id":["BF6605600"],"URL":"https:\/\/doi.org\/10.1038\/sj.bjc.6605600","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,4]]}}}